Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study - PubMed
. 2005 Jul;366(9480):144-50.
doi: 10.1016/S0140-6736(05)66788-8.
Ousman Secka, George Lahai, Nellie Lloyd-Evans, Alpha Njie, Stanley Usen, Claire Oluwalana, Stephen Obaro, Martin Weber, Tumani Corrah, Kim Mulholland, Keith McAdam, Brian Greenwood, Paul J M Milligan
Affiliations
- PMID: 16005337
- DOI: 10.1016/S0140-6736(05)66788-8
Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study
Richard A Adegbola et al. Lancet. 2005 Jul.
Abstract
Background: Routine immunisation of infants in The Gambia with a Haemophilus influenzae type b (Hib) polysaccharide-tetanus toxoid conjugate vaccine began in May, 1997. We investigated the effectiveness of the vaccine when delivered through the expanded programme on immunisation and the effect of national immunisation on incidence of Hib disease.
Methods: Surveillance for Hib disease was maintained in the western half of The Gambia using standard methods with an emphasis on meningitis. We estimated vaccine efficacy using the case control method, and vaccine coverage and population denominators for incidence rates using a cluster sample survey. Prevalence of Hib carriage in a sample of 1-2-year old children attending health centres for vaccination was ascertained with oropharyngeal swabs plated onto antiserum agar.
Findings: Between May, 1997, and April, 2002, a total of 5984 children were examined for possible Hib infections. 49 children had Hib disease, 36 of whom had meningitis. The annual incidence rates of Hib meningitis before any use of the vaccine (1990-93) dropped from over 200 per 100,000 children aged younger than 1 year to none per 100,000 in 2002, and from 60 to no cases per 100,000 in children younger than 5 years. The prevalence of Hib carriage decreased from 12% to 0.25% (p<0.0001). Two doses of vaccine were needed for direct protection from Hib disease (vaccine efficacy 94%, 95% CI 62-99). Since most children received a protective dose after the age of greatest disease risk, indirect effects were important in reducing disease incidence.
Interpretation: The Gambian Hib immunisation programme reduced the occurrence of Hib disease despite irregular vaccine supply. The effect of the programme in The Gambia has important implications for the introduction of the vaccine into routine immunisation programmes of other developing countries.
Comment in
-
Hib vaccines for all the world's children?
Clemens J, Jodar L. Clemens J, et al. Lancet. 2005 Jul 9-15;366(9480):101-3. doi: 10.1016/S0140-6736(05)66789-X. Lancet. 2005. PMID: 16005315 No abstract available.
Similar articles
-
Hib vaccines for all the world's children?
Clemens J, Jodar L. Clemens J, et al. Lancet. 2005 Jul 9-15;366(9480):101-3. doi: 10.1016/S0140-6736(05)66789-X. Lancet. 2005. PMID: 16005315 No abstract available.
-
Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, Weber M, Palmer A, Schneider G, Jobe K, Lahai G, Jaffar S, Secka O, Lin K, Ethevenaux C, Greenwood B. Mulholland K, et al. Lancet. 1997 Apr 26;349(9060):1191-7. doi: 10.1016/s0140-6736(96)09267-7. Lancet. 1997. PMID: 9130939 Clinical Trial.
-
Ribeiro GS, Lima JB, Reis JN, Gouveia EL, Cordeiro SM, Lobo TS, Pinheiro RM, Ribeiro CT, Neves AB, Salgado K, Silva HR, Reis MG, Ko AI. Ribeiro GS, et al. Vaccine. 2007 May 30;25(22):4420-8. doi: 10.1016/j.vaccine.2007.03.024. Epub 2007 Mar 30. Vaccine. 2007. PMID: 17449150
-
Slack M, Esposito S, Haas H, Mihalyi A, Nissen M, Mukherjee P, Harrington L. Slack M, et al. Expert Rev Vaccines. 2020 Oct;19(10):903-917. doi: 10.1080/14760584.2020.1825948. Epub 2020 Oct 10. Expert Rev Vaccines. 2020. PMID: 32962476 Review.
-
Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N, Lee E, Levine OS, Hajjeh R, Mulholland K, Cherian T; Hib and Pneumococcal Global Burden of Disease Study Team. Watt JP, et al. Lancet. 2009 Sep 12;374(9693):903-11. doi: 10.1016/S0140-6736(09)61203-4. Lancet. 2009. PMID: 19748399 Review.
Cited by
-
Levine MM. Levine MM. BMC Biol. 2010 Oct 4;8:129. doi: 10.1186/1741-7007-8-129. BMC Biol. 2010. PMID: 20920375 Free PMC article. Review.
-
Armitage EP, Camara J, Bah S, Forster AS, Clarke E, Kampmann B, de Silva TI. Armitage EP, et al. Vaccine. 2018 Mar 20;36(13):1772-1780. doi: 10.1016/j.vaccine.2018.02.037. Epub 2018 Feb 23. Vaccine. 2018. PMID: 29483030 Free PMC article.
-
Challenges of evaluating and modelling vaccination in emerging infectious diseases.
Madewell ZJ, Dean NE, Berlin JA, Coplan PM, Davis KJ, Struchiner CJ, Halloran ME. Madewell ZJ, et al. Epidemics. 2021 Dec;37:100506. doi: 10.1016/j.epidem.2021.100506. Epub 2021 Oct 5. Epidemics. 2021. PMID: 34628108 Free PMC article.
-
Risk factors associated with non-vaccination in Gambian children: a population-based cohort study.
Young B, Sarwar G, Hossain I, Mackenzie G. Young B, et al. Trans R Soc Trop Med Hyg. 2022 Nov 1;116(11):1063-1070. doi: 10.1093/trstmh/trac051. Trans R Soc Trop Med Hyg. 2022. PMID: 35696088 Free PMC article.
-
Progress in vaccination against Haemophilus influenzae type b in the Americas.
Danovaro-Holliday MC, Garcia S, de Quadros C, Tambini G, Andrus JK. Danovaro-Holliday MC, et al. PLoS Med. 2008 Apr 22;5(4):e87. doi: 10.1371/journal.pmed.0050087. PLoS Med. 2008. PMID: 18433291 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous